

**Unaudited Financial Results (Provisional)
for the Quarter and Nine Months ended 31st December, 2006**

(Rs. in Lac)

Particulars	For the quarter ended		For the nine months ended		Year ended
	31.12.2006 (Unaudited)	31.12.2005 (Unaudited)	31.12.2006 (Unaudited)	31.12.2005 (Unaudited)	31.03.2006 (Audited)
Turnover	19,763	11,307	61,122	41,050	54,797
Less: Excise Duty	51	304	644	927	1,162
Income from Operations	19,712	11,003	60,478	40,123	53,635
Other Income	407	156	2,974	328	709
Total Income	20,119	11,159	63,452	40,451	54,345
(Increase) / Decrease in Stocks	(580)	(1,790)	(298)	2,818	30
Consumption of Materials & bought outs	10,745	7,399	28,133	17,497	26,724
Manufacturing Expenses	514	476	1,556	1,361	1,986
Personnel Expenses	1,628	1,106	4,377	2,589	3,588
Others	2,935	1,877	7,965	6,191	8,969
Total Expenditure	15,242	9,068	41,733	30,456	41,297
Interest	112	233	1,192	813	1,182
Gross Profit after Interest but before Depreciation & Tax	4,765	1,858	20,527	9,182	11,866
Depreciation	917	465	2,481	1,286	1,822
Operating Profit before Tax & Prior Period Items	3,848	1,393	18,046	7,896	10,044
Prior Period Expenses	-	-	-	10	23
Profit before Tax	3,848	1,393	18,046	7,886	10,021
Provision for taxation	595	248	4,378	1,983	2,559
Fringe Benefits Tax	15	50	155	120	250
Deferred Tax Liabilities/ (Assets)	528	576	1,174	837	1,117
Net Profit	2,710	519	12,339	4,946	6,094
Paid-up Share Capital					
Equity (Face Value Re.1/- per Share)	658	571	658	571	571
Preference (Face Value Rs.10/- per Share)	-	9,043	-	9,043	9,043
Reserves & Surplus					15,460
E.P.S. (Rs.)	4.50	0.71	20.38	8.08	9.86
	4.11	0.71	18.64	8.08	9.64
Aggregate of Public Shareholding					
Number of Shares	22,204,164	13,584,000	22,204,164	13,584,000	13,584,000
Percentage of holding	33.73	23.74	33.73	23.74	23.74

Unaudited Segment wise Revenue, Results and Capital Employed

Particulars	For the quarter ended		For the nine months ended		Year ended
	31.12.2006 (Unaudited)	31.12.2005 (Unaudited)	31.12.2006 (Unaudited)	31.12.2005 (Unaudited)	31.03.2006 (Audited)
Segment Revenue					
A. Vaccines	15,092	7,836	47,506	29,839	40,669
B. Formulations	4,812	3,148	13,228	10,211	12,965
C. Research & Development	-	110	53	129	139
Gross Sales/ Income from Operations	19,904	11,094	60,787	40,179	53,773
Less : Inter Segment Revenue	-	-	-	-	-
Net Sales/ Income from Operations	19,904	11,094	60,787	40,179	53,773
Segment Results					
A. Vaccines	5,914	3,477	21,332	12,192	16,022
B. Formulations	525	353	2,161	1,855	2,218
C. Research & Development	(1,431)	(565)	(3,634)	(1,830)	(2,670)
Total	5,008	3,265	19,859	12,217	15,570
Less : Interest & Financial Charges	148	315	1,316	895	1,182
Unallocated Overheads net of unallocated Income	1,012	1,557	497	3,426	4,344
Prior Period Expenses	-	-	-	10	23
Total Profit Before Tax	3,848	1,393	18,046	7,886	10,021
Capital Employed					
A. Vaccines	24,635	9,950	24,635	9,950	19,976
B. Formulations	21,435	10,110	21,435	10,110	14,493
C. Research & Development	9,400	5,738	9,400	5,738	7,654
Capital employed in Segments	55,470	25,798	55,470	25,798	42,123
Add: Unallocable Assets Less Liabilities	(3,053)	381	(3,053)	381	(17,047)
Total Capital employed	52,417	26,179	52,417	26,179	25,076

Notes:

1. The above financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 17th January, 2007 and 18th January, 2007 respectively.

2. During the quarter, Foreign Currency Convertible Bonds (FCCBs) aggregating US\$ 55 Million (Tranche 1 US\$ 50 Million & Tranche 2 US\$ 5 Million) have been converted into Equity Shares of Re.1/- each at a premium of Rs.275.30 and Rs.356.57 per Share respectively, thereby increasing paid-up Equity Share Capital by Rs.8.6 Million and Share Premium Account by Rs.2419.09 Million. As a result of this, the public shareholding has increased to 33.73% as against 23.77% of the total equity share capital before such conversion.

3. Out of net proceeds of US\$ 96.92 Million (against FCCB issue of US\$100 million during February, 2006), an amount of US\$55 Million (Rs.2427.70 Million) has been remitted to India upon conversion of FCCBs, US\$22.84 Million (Rs.1,032.04 Million) has been remitted to India for Capex, etc., US\$ 4.08 Million (Rs.182.68 Million) has been used for repayment of FC Loan/ Investment abroad and balance amount of US\$15 Million (Rs.662.10 Million) is invested in Fixed Deposits with Bank abroad.

4. During the quarter, the Company has entered into a joint venture and made investment of Rs.168.07 Million (£1.94 Million) for acquiring 10% of expanded share capital in M/s **Cambridge Biostability Ltd., Cambridge, U.K.**

5. During the quarter, the Company's in-house **R&D Centre at New Delhi got recognition** from Government of India, Ministry of Science & Technology, New Delhi.

6. The Company had redeemed 4,34,34,914 - 4.5% Non-convertible Redeemable Preference Shares (Series - III) of Rs.10/- each on 4th December, 2006. Further, dividend @4.5% (on pro-rata time basis) aggregating Rs.2,03,54,084/-, has been paid on 04.12.2006 as Interim Dividend in respect of financial year 2006-07, on Preference Shares Series - III redeemed during the year.

7. During the quarter, the Company launched **Metlong P-15 and 30** Tablets (for type II Diabetes), **Threpro 2.5 and 5** Capsules (for management of Hypertension), **Myelogen Forte** (for prevention / delaying of Diabetic Neuropathy), **Kondro OD** (for prevention / delaying the progression of Osteoarthritis), **Nimulid HF** (for high fever), **Dolzero** (for treatment of severe pain), **Toff Expectorant & Toff DC** Syrup (for productive cough), **Upright SP** (anti-inflammatory, analgesic with wound healing properties), **Upright MR** (anti-inflammatory, analgesic with muscle relaxant) and **Cefmentin 200** (antibiotic).

8. Status of Investors' complaints [in nos.] during the quarter, pursuant to clause 41 of listing agreement: Opening [0]; Received [3]; Disposed [2]; Closing [1].

9. The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary.

New Delhi
January 18, 2007

For and on behalf of the Board
Soshil Kumar Jain
Chairman

Panacea Biotec Ltd.
Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab
Website : <http://www.panacea-biotec.com>